Evidence map›Paper›PMID 34603508›Full record

ReviewTherapeutic advances in urology

Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review.

Mojtaba Shafiekhani, Anahita Dehghani, Mina Shahisavandi, Seyed Ali Nabavizadeh, Maryam Kabiri, Amir Hossein Hassani, Abdolreza Haghpanah

Open access · goldAbstract readReview
In one paragraph

Review in Therapeutic advances in urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mojtaba ShafiekhaniShiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, IranDepartment of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Anahita DehghaniShiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mina ShahisavandiEpilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Seyed Ali NabavizadehStudent Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Maryam KabiriStudent Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Amir Hossein HassaniStudent Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Abdolreza HaghpanahAssistant Professor of Urology, Endourology Ward, Urology Department, Shiraz University of Medical Sciences, Shiraz, 71348-44119, Iran Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, 71348-44119, Iran.ORCID https://orcid.org/0000-0002-9728-7049
Shiraz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One year after the prevalence of the novel coronavirus pandemic, some aspects of the physiopathology, treatment and progression of coronavirus 2019 disease (COVID-19) have remained unknown. Since no comprehensive study on the use of urological medications in patients with COVID-19 has been carried out, this narrative review aimed to focus on clinically important issues about the treatment of COVID-19 and urologic medications regarding efficacy, modifications, side effects and interactions in different urologic diseases. In this review, we provide information about the pharmacotherapeutic approach toward urologic medications in patients with COVID-19 infection. This study provides an overview of medications in benign prostatic hyperplasia, prostate cancer, impotence and sexual dysfunction, urolithiasis, kidney transplantation and hypertension as the most frequent diseases in which the patients are on long-term medications. Also, the effect of urologic drugs on the efficacy of vaccination is briefly discussed.

Indexed as

COVID-19drug interactionmajor urological diseases

Identifiers

PMID34603508
PMCPMC8481748
OpenAlexW3202130909

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.